Zoetis Inc - Ordinary Shares - Class A
ZTS
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
May 7, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
116% upsideUndervalued by 116% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $32.57 Billion |
|---|---|
| Enterprise Value | $31.03 Billion |
| Dividend Yield | $2.06 (2.65%) |
| Earnings per Share | $6.03 |
| Beta | 0.86 |
| Outstanding Shares | 422,100,000 |
Return
| Return on Equity | 81.75% |
|---|---|
| Return on Assets | 17.44% |
| Return on Invested Capital | 27.12% |
Valuation & Multiples
| P/E Ratio | 12.41 |
|---|---|
| PEG | -260.97 |
| Price to Sales | 3.53 |
| Price to Book Ratio | 11.08 |
| Enterprise Value to Revenue | 3.26 |
| Enterprise Value to EBIT | 8.73 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7266▲ 34.76% |
|---|---|
| Total Calls | 1,951,817▼ 36.82% |
| Total Puts | 1,418,208▲ 21.12% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 92.04%▼ 6.26% |
|---|---|
| Total Invested | $48.18B▼ 6.94% |
| Investors Holding | 1,647▼ 78.00% |
ESG Score
No data
About Zoetis Inc
9,200 employees
CEO: Kristin Peck Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines...
Relevant Senate Committees
This committee provides the technical analysis and revenue estimates for all tax legislation. Its work directly influences the tax policies that determine Zoetis's corporate tax burden and financial strategies, providing crucial insight for members.
As the primary committee for taxation and trade, it directly impacts Zoetis's corporate profitability through tax policy (e.g., R&D credits, corporate rates) and its global operations through trade agreements and tariffs.
This committee allocates federal spending, directly impacting funding for agencies like the USDA (relevant to animal health programs) and NIH (for broader research that may benefit animal health), influencing revenue streams and R&D opportunities for Zoetis.
Zoetis's significant business with livestock producers and farm animals places it directly under the influence of this committee, which shapes agricultural policy, the Farm Bill, and related regulations impacting its core customer base and product demand.
This committee oversees the FDA, which includes the Center for Veterinary Medicine responsible for approving animal drugs, vaccines, and diagnostics. Its regulatory decisions are critical to Zoetis's product pipeline and market access.